title: Might analysis, synthesis and metabolism of CLA contribute to explain the biological effects of CLA?
abstract: Conjugated Linoleic Acids (CLA) are of great interest for analysts since techniques have been developed to determine the dietary occurrence of CLA with a good accuracy. CLA is found in animal products from ruminant sources as the result of biohydrogenation of polyunsaturated fatty acids in the rumen and as the consequence of the delta-9 desaturation of vaccenic acid in animal tissues. CLA can also be obtained in the laboratory by isomerisation of linoleic acid or by total chemical synthesis. While the "natural" isomer is rumenic acid (9c,11t-18:2), synthetic mixtures contain mainly two isomers: the 9c,11t- and the 10t,12c-18:2. Although CLA have been shown to be metabolized into desaturated and chain elongated products, it remains unclear whether these so-formed conjugated metabolites may be involved in the effects of CLA on fatty acid metabolism. Experiments carried out on animal models with CLA have shown different health benefits: anticarcinogenic, antiatherosclerotic effects, modulation of body composition , the "natural" CLA (9c,11t-18:2) being closely related to the protection against cancer and the 10t,12c-18:2 to the reduction of the fat mass. Nevertheless, recent findings have suggested adverse effects in mice. Most of the studies carried out on humans concern the influence of CLA on body composition and its possible inverse association with cancer. Since the results are still controversial and since very few data dealing with the safety of using CLA in long term feeding studies have so far been published, further works are warranted to consider the benefits of CLA for humans.
authors.affiliation: National Instiute for Research on Agronomgy, Dijon, France. Lionel.Bretillon@dijon.inra.fr
authors.forename: L
authors.initials: L
authors.lastname: Bretillon
authors.forename: J L
authors.initials: JL
authors.lastname: Sébédio
authors.forename: J M
authors.initials: JM
authors.lastname: Chardigny
mesh_terms: D000818:Animals; D001161:Arteriosclerosis / Q000517:prevention & control*; D001823:Body Composition; D004195:Disease Models, Animal; D006801:Humans; D019787:Linoleic Acid / Q000032:analysis / Q000096:biosynthesis; D044243:Linoleic Acids, Conjugated / Q000032:analysis / Q000096:biosynthesis / Q000627:therapeutic use; D009369:Neoplasms / Q000517:prevention & control*; D009829:Oleic Acids / Q000032:analysis / Q000096:biosynthesis; D044242:Trans Fatty Acids
chemical_list: D044243:Linoleic Acids, Conjugated; D009829:Oleic Acids; D044242:Trans Fatty Acids; C046938:9,11-linoleic acid; D019787:Linoleic Acid; C050413:11-octadecenoic acid